FHA
ACAD icon

First Horizon Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

First Horizon Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-338
Closed -$10.6K – 2287
2023
Q4 		$10.6K Buy
+338
New +$8.07K ﹤0.01% 1575

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Horizon Advisors's ACAD Position: Q1 2024 in Review

First Horizon Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 338 shares — an estimated $10.6K sold.

First Horizon Advisors first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $10.6K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • First Horizon Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • First Horizon Advisors sold 338 Acadia Pharmaceuticals shares in Q1 2024, an estimated $10.6K.
  • First Horizon Advisors first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • First Horizon Advisors's Acadia Pharmaceuticals position peaked at $10.6K in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on First Horizon Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.